Clinical Trial

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-08-12; most recent amendment 2026-06-10.
Status change: Active, Not Recruiting → Recruiting 2024-01-26
Status change: Recruiting → Active, Not Recruiting 2023-06-21
Status change: Not Yet Recruiting → Recruiting 2022-10-14
Trial Details
NCT Number NCT05501756
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Conditions Allogeneic Hematopoietic Cell Transplantation
Enrollment 60 participants
Start Date 2023-01-11
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-12